{"id":"NCT03349060","sponsor":"Pfizer","briefTitle":"Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis","officialTitle":"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-04965842 MONOTHERAPY IN SUBJECTS AGED 12 YEARS AND OLDER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-07","primaryCompletion":"2019-03-26","completion":"2019-03-26","firstPosted":"2017-11-21","resultsPosted":"2019-12-10","lastUpdate":"2019-12-10"},"enrollment":387,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dermatitis, Atopic"],"interventions":[{"type":"DRUG","name":"PF-04965842 100 mg","otherNames":[]},{"type":"DRUG","name":"PF-04965842 200 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"PF-04965842 100 mg","type":"EXPERIMENTAL"},{"label":"PF-04965842 200 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.","primaryOutcome":{"measure":"Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"PF-04965842 100 mg","deltaMin":23.7,"sd":null},{"arm":"PF-04965842 200 mg","deltaMin":43.8,"sd":null},{"arm":"Placebo","deltaMin":7.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0037"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":88,"countries":["United States","Australia","Canada","Czechia","Germany","Hungary","Poland","United Kingdom"]},"refs":{"pmids":["40028832","39104653","38896380","37988255","37949351","35763326","35462428","35342978","35061234","34743361","34406619","33954933","32711801"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=B7451012"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":156},"commonTop":["Nasopharyngitis","Nausea","Dermatitis atopic","Headache","Upper respiratory tract infection"]}}